Invasive Bladder Urothelial Carcinoma

Curated

civic

Invasive Bladder Urothelial Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived25 of 25show fewer
→ investigated in trials for	Gemcitabinesmall molecule 9 trials (7 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 8 trials (6 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 8 trials (7 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Enfortumab Vedotinadc 4 trials (4 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 4 trials (4 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Avelumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Mitomycinsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Tremelimumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Vinblastinesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Erdafitinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nadofaragene Firadenovecgene therapy 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Pegfilgrastimother 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Sacituzumab Govitecanadc 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →

Invasive Bladder Urothelial Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived25 of 25show fewer

→ investigated in trials for

Gemcitabinesmall molecule

9 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

8 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

8 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enfortumab Vedotinadc

4 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

4 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avelumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mitomycinsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tremelimumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinblastinesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bicalutamidesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erdafitinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nadofaragene Firadenovecgene therapy

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegfilgrastimother

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pemetrexedsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sacituzumab Govitecanadc

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Invasive Bladder Urothelial Carcinoma studied in …STUDIED_INderived10 of 45show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061964Phase 2 · recruiting Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Non-Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06605404recruiting Pan-tumor MRD Study · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07332351Phase 2 · not yet recruiting Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 45 trials mapped (31 active)	—	—	Invasive Bladder Giant Cell Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07822373Phase 2 · not yet recruiting A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 45 trials mapped (31 active)	—	—	Invasive Bladder Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06503614Phase 2 · recruiting A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)	—	—	Non-Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →

Invasive Bladder Urothelial Carcinoma studied in …STUDIED_INderived10 of 45show all (up to 200)

→ studied in

NCT03866382Phase 2 · recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed

→ studied in

NCT05987241Phase 2/Phase 3 · recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed

→ studied in

NCT07061964Phase 2 · recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed

Non-Muscle Invasive Bladder Urothelial Carcinoma

→ studied in

NCT06770582Phase 2 · recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed

→ studied in

NCT06605404recruiting

Pan-tumor MRD Study · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed

→ studied in

NCT07332351Phase 2 · not yet recruiting

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed

Invasive Bladder Giant Cell Urothelial Carcinoma

→ studied in

NCT07667335Phase 1/Phase 2 · recruiting

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 45 trials mapped (31 active)

—

Observed

→ studied in

NCT07822373Phase 2 · not yet recruiting

A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed

Invasive Bladder Sarcomatoid Urothelial Carcinoma

→ studied in

NCT02812420early Phase 1 · active not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 45 trials mapped (31 active)

—

Observed

Non-Muscle Invasive Bladder Urothelial Carcinoma

→ studied in

NCT06503614Phase 2 · recruiting

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · condition mapped ONTOLOGY_EXACT · 45 trials mapped (31 active)

—

Observed